Evidence map›Paper›PMID 27866280›Full record

ReviewJournal of neural transmission (Vienna, Austria : 1996)2018

Proteasome-mediated degradation of tyrosine hydroxylase triggered by its phosphorylation: a new question as to the intracellular location at which the degradation occurs.

Akira Nakashima, Yu Kodani, Yoko S Kaneko, Hiroshi Nagasaki, Akira Ota

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of neural transmission (Vienna, Austria : 1996), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Human tyrosine hydroxylase in Parkinson's disease and in related disorders.Journal of neural transmission (Vienna, Austria : 1996) · 2019
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Akira NakashimaDepartment of Physiological Chemistry, Fujita Health University School of Medicine, Toyoake, 470-1192, Aichi, Japan. anakashi@fujita-hu.ac.jp.
Yu KodaniDepartment of Physiology, Fujita Health University School of Medicine, Toyoake, 470-1192, Aichi, Japan.
Yoko S KanekoDepartment of Physiology, Fujita Health University School of Medicine, Toyoake, 470-1192, Aichi, Japan.
Hiroshi NagasakiDepartment of Physiology, Fujita Health University School of Medicine, Toyoake, 470-1192, Aichi, Japan.
Akira OtaDepartment of Physiology, Fujita Health University School of Medicine, Toyoake, 470-1192, Aichi, Japan.
Fujita Health University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tyrosine hydroxylase (TH) is the rate-limiting enzyme in catecholamine biosynthesis, and its stability is a fundamental factor to maintain the level of the catecholamines in cells. However, the intracellular stability of TH determined by the degradation remains unknown; although the TH molecule phosphorylated at its Ser19 was observed in the nucleus, and the phosphorylation suspected to trigger its proteasome-mediated degradation. Computer-assisted analysis using the cNLS Mapper program predicted that two sequences of nuclear localization signals (NLS) exist in the N-terminus of TH molecule containing the phosphorylation sites Ser19, Ser31, and Ser40 (Pro

Indexed as

Amino Acid SequenceAnimalsCell NucleusCytoplasmHumansIntracellular FluidPhosphorylationProteasome Endopeptidase ComplexTyrosine 3-MonooxygenaseProteasome Endopeptidase ComplexTyrosine 3-MonooxygenaseImportinNLSNuclear importNuclear localization signalsPhosphorylationProteasomeTyrosine hydroxylase

Identifiers

PMID27866280
OpenAlexW2555472459

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.